免疫检查点抑制剂治疗患者的感染并发症
该研究从法国前瞻性登记库随机抽取200例接受抗PD-1/PD-L1抑制剂的患者进行病历回顾,发现18%的患者发生感染,中位发生时间为开始ICI治疗后47天,感染以肺部最常见,均为轻症且无感染相关死亡或机会性感染,未观察到皮质类固醇或免疫抑制剂使用与感染发生的关联。
要点
- 抗PD-1/PD-L1治疗患者感染率为18%,以轻症肺部感染为主,门诊处理即可。
- 未发生感染相关死亡或机会性感染。
- 未发现皮质类固醇或免疫抑制剂使用与感染发生相关。
核心结论
- 接受抗PD-1/PD-L1免疫检查点抑制剂治疗的患者感染率为18%,无严重或机会性感染。
- 感染的发生与皮质类固醇或免疫抑制剂使用无关联。
研究设计与样本
- 从法国前瞻性登记库中随机抽取200例接受抗PD-1/PD-L1抑制剂治疗的患者进行病历回顾。
- 记录人口学数据、免疫相关不良事件(irAEs)发生情况、免疫抑制剂使用及结局。
主要发现
- 感染总体轻微,患者均门诊处理;无感染相关死亡,无机会性感染。
- 47例因癌症症状或irAEs使用类固醇,5例在免疫治疗期间使用免疫抑制剂;未观察到皮质类固醇或免疫抑制剂使用与感染发生的关联。
临床怎么用
- 抗PD-1/PD-L1治疗期间发生感染多为轻症,可门诊抗生素治疗,无需过度担忧严重感染。
- 使用皮质类固醇或免疫抑制剂的患者未显示感染风险增加,但仍需个体化评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Immune checkpoint inhibitor (ICI) antibodies constitute a new generation of cancer treatments, associated with immune-related adverse events (irAEs). A previous retrospective study of patients with metastatic melanoma (treated mostly with anti-CTLA4 antibodies) reported a serious infection rate of 7.3%. The main risk factors were corticoids and infliximab use. We sought to describe infections and risk factors among patients receiving anti-PD-1/PD-L1 ICIs. PATIENTS AND METHODS: We reviewed 200 medical records sampled randomly from a French prospective registry, which collates patients treated with anti-PD-1/PD-L1 ICIs. We recorded demographic data, the occurrence of irAEs, immunosuppressant use, and the outcome. RESULTS: Thirty-six patients (18%) experienced an infection by a median (interquartile range) of 47 (19.2-132) days after initiation of the ICI. Twenty-one patients (58.3%) had a lung infection, seven (19.4%) had a skin infection, seven (19.4%) had a urinary tract infection, and all of them received antibiotics. The infection was generally mild, and the patients were treated as outpatient. There were no infection-related deaths and no opportunistic infection. Sixty percent of the patients were being treated for metastatic melanoma and 35.5% for non-small cell lung cancer, and 106 irAEs (mostly grade II) were reported. Forty-seven patients received steroids for cancer symptoms or irAEs, and five received immunosuppressants during the immunotherapy. We did not observe any association between corticosteroid or immunosuppressant use and the occurrence of an infection. CONCLUSION: The infection rate in patients treated with an anti-PD-1/PD-L1 ICI was 18%, without any severe or opportunistic infection. The occurrence of an infection was not associated with corticosteroid or immunosuppressant use.
引用
- Karam JD, Noel N, Voisin AL, et al. Infectious complications in patients treated with immune checkpoint inhibitors. Eur J Cancer. 2020. PMID: 33137589. doi:10.1016/j.ejca.2020.09.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。